Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 2Phase 2 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Lymphoma 35Small Cell Lung Carcinoma 34Leukemia 34Lung Neoplasms 25Leukemia, Myeloid, Acute 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Large B-Cell, Diffuse 19Neuroblastoma 15Lymphoma, Non-Hodgkin 15Carcinoma, Non-Small-Cell Lung 14Leukemia, Erythroblastic, Acute 13Hodgkin Disease 13Leukemia, Myelomonocytic, Acute 12Leukemia, Monocytic, Acute 12Leukemia, Megakaryoblastic, Acute 12Sarcoma 11Lymphoma, Follicular 10Burkitt Lymphoma 10Lymphoma, Large-Cell, Immunoblastic 9Testicular Neoplasms 7Teratoma 7Myelodysplastic Syndromes 7Congenital Abnormalities 7Multiple Myeloma 6Endodermal Sinus Tumor 6Anemia, Refractory, with Excess of Blasts 6Testicular Germ Cell Tumor 5Ovarian Neoplasms 5Neuroectodermal Tumors, Primitive, Peripheral 5Central Nervous System Neoplasms 5

Interventions

Etoposide 3Cisplatin 2Carboplatin 2belotecan 1atezolizumab 1RRx-001 1PM 01183 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Small Cell × Etoposide × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT03699956 2024-03-26

REPLATINUM

EpicentRx, Inc.

Phase 3 Terminated
18 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00826644 2021-08-09

COMBAT

Chonnam National University Hospital

Phase 3 Completed
147 enrolled
Thoracic

Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡